References
- Tanda ML, Piantanida E, Liparulo L, et al. Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab. 2013;98:1443–1449.
- Lazarus JH. Epidemiology of Graves’ orbitopathy (GO) and relationship with thyroid disease. Best Pract Res Clin Endocinol Metab. 2012;26:273–279.
- Bartalena L. Graves’ orbitopathy: imperfect treatment for a rare disease. Eur Thyroid J. 2013;2:259–269.
- Salvi M, Campi I. Medical treatment of Graves’ orbitopathy. Horm Metab Res. 2015;47:779–788.
- Kahaly GJ, Pitz S, Hommel G, et al. Randomized, single-blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab. 2005;90:5234–5240.
- Bartalena L, Krassas GE, Wiersinga W, et al. European group on Graves’ orbitopathy: efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J Clin Endocrinol Metab. 2012;97:4454–4463.
- Bradley EA, Gower EW, Bradley DJ, et al. Orbital radiation for Graves’ ophthalmopathy: a report by the American Academy of Ophthalmology. Ophthalmology. 2008;115:398–409.
- Dolman PJ, Rath S. Orbital radiotherapy for thyroid eye disease. Curr Opinion Ophthalmol. 2012;23:427–432.
- Salvi M, Vannucchi G, Campi I, et al. Efficacy of rituximab treatment for thyroid-associated ophtahlmopathy as a result of intra-orbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol. 2006;154:511–517.
- El Fassi D, Nielsen CH, Hasselbalch HC, et al. Treatment-resistant severe, active Graves’ ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid. 2006;16:709–710.
- Khanna D, Chong KK, Afifiyan NF, et al. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology. 2010;117:133–139.
- Salvi M, Vannucchi G, Curro N, et al. Small dose of rituximab for Graves’ orbitopathy: new insights into the mechanism of action. Arch Ophthalmol. 2012;130:122–124.
- Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158:273–285.
- Selva D, Chen C, King G. Late reactivation of thyroid orbitopathy. Clin Exp Ophthalmol. 2004;32:46–50.
- Salvi M, Vanuchi G, Beck-Peccoz P. Potential utility of rituximab for Graves’ orbitopathy. J Clin Endocrinol Metab. 2013;98:4291–4299.
- Erdei A, Paragh G, Kovacs P, et al. Rapid response to and long-term effectiveness of anti-CD20 antibody in conventional therapy resistant Graves’ orbitopathy: a five-year follow-up study. Autoimmunity. 2014;47:548–555.
- Salvi M, Vanuchi G, Curro N, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015;100:422–431.
- Stan MN, Garrity JA, Carranza Leon BG, et al. Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab. 2015;100:432–441.
- Bartalena L, Baldeschi L, Boboridis K, et al. European thyroid association/European group on Graves’ orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J. 2016;5:9–26.
- Visentini M, Tinelli C, Colantuono S, et al. Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: phase II clinical trial and systematic review. Autoimmun Rev. 2015;14:889–896.
- M, Campos GGDe Oliveira FK. Updated systematic review and meta-analysis of randomized controlled trials comparing low-dose versus high-dose rituximab for rheumatoid arthritis. Clin Rheumatol. 2015;34:1801-1805.